Popular on TelAve
- Mother's Day Wake-Up Call for Maternal Health: New Initiative Demands Better Postpartum Support
- Transportation and Communications Sector SG&A Benchmarks 2025 edition released
- The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
- Whistleblower Seeks SEC and Shareholder Review of Cogent Communications' 2003 Acquisition of FNSI
- Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
- NASDAQ Uplisting for Higher Market Exposure and Wide Corporate Benefits to AI Boosted Marketing Company On Track Towards $1 Billion Revenue by 2027
- Cogent Communications Faces Federal Scrutiny Over Fraudulent Acquisition and 22-Year Corporate Cover-Up
- Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
- CCHR Florida: Mental Health Awareness Month Open House
Similar on TelAve
- Zareef Hamid on the Rise of AI-Native Organizations
- Zareef Hamid on Real-Time, Unified Payment Systems Driving the Global Economy
- A World First: The Global Naturism & Nudism Index Launched by NaturismRE™
- Garage Door Scam Alert: Superior Overhead Doors Warns Tulsa Homeowners About Red Flags
- Coinbase recommends using Winner Mining Classic hashrate for the benefit of everyone
- Detroit Grand Prix High Profile Media Exposure, $100 Million Financing for Major Acquisition & Growth Strategy; Remote Lottery Platform: Lottery.com
- 6 Love Sports and Eight Sleep Announce Partnership Miami Women's Padel League Rebranded as the Eight Sleep Miami Women's Padel League by 6 Love Sports
- Al-Tabbaa & Hackett: Fixed Rates Improve For Savers
- $400 Million Run Rate in 2025 for Global Telcom Leader as a Result of Definitive Fintech Acquisition, Fast-Tracking $1 Billion Growth Plan: IQSTEL Inc
- Chosen Launches Mobile Family Closet to Serve Foster, Adoptive, and Kinship Families Across Southeastern Wisconsin
Acquisition of Clinics Generating $100 Million to Complement Progress on Accelerated Drug Approval for Bipolar Depression NRx Pharmaceuticals: NRXP
TelAve News/10838656
NRXP: Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics.
MIAMI - TelAve -- NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
On August 26th NRXP announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, NRXP has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. NRXP anticipates potential operations in the United States, France, and the United Kingdom.
More on TelAve News
This non-dilutive acquisition funding is in addition to the over $60 million in potential equity funding previously offered upon public listing of HOPE Therapeutics shares on a public exchange. Additional information to be presented by NRXP at upcoming HC Wainwright Annual Global Investment Conference in New York, September 9-11, 2024.
NRXP has formed partnerships to license clinical trial data from a French Government-funded trial and two NIH-funded trials all of which demonstrate efficacy of racemic Intravenous ketamine against depression and two of which demonstrate statistically significant benefit vs suicidality.
In March 2024 NRXP demonstrated the formulation of a pH neutral patentable form of IV ketamine that it anticipates will have widespread applicability both in treatment of depression and chronic pain.
NRXP presented final data from the recently completed phase 2b/3 trial of NRX-101 in suicidal bipolar depression4 at the American Society of Clinical Psychopharmacology's annual meeting. These data demonstrated a significantly improved safety profile versus the standard of care, as demonstrated by a clinically significant reduction in akathisia (P=0.025) and time to sustained remission from suicidality (P=0.05). Akathisia is an adverse event seen with antidepressant medications considered by many experts to be a precursor to suicide. Given the vital need for safer medications in this at-risk population, we plan to submit an NDA for Accelerated Approval to the US FDA for treatment of bipolar depression patients with suicidality or akathisia, based on these data as well as additional data from our STABIL-B5 trial.
HOPE Therapeutics, is an NXRP subsidiary that will focus on the delivery of advance psychiatric treatments, including ketamine-focused treatment for depression and suicidality. Unlike the core business of NRXP, that is focused on biotechnology Research and Development, HOPE is organized around consolidating existing best-in-class clinics into a nationwide network. This has been done previously and without much success with clinics that are not necessarily psychiatrist-led. With Hope ownership as an asset of NRXP, this will further strengthen the NRXP balance sheet and aims to further enhance shareholder value.
More on TelAve News
NRX-101 for Treatment of Chronic Pain:
In 2023, NRXP licensed US Patent 8,653,120 for the use of DCS in chronic pain and filed a now-accepted Investigational New Drug (IND) application with the FDA to initiate commercial drug development of NRX-101 in chronic pain. Data lock has now been achieved in a 200-person randomized prospective trial funded by the US DOD.
During Q3 2023, NRXP tested NRX-101 and its components against resistant pathogens that appear on the Congressionally mandated Qualified Infectious Disease Product (QIDP) list and proved in vitro effectiveness against antibiotic-resistant E. coli, Pseudomonas, and Acinetobacter. Accordingly, NRXP was granted QIDP designation, Fast Track Designation, and Priority Review by the US FDA in January 2024.
Should NRX-101 succeed in clinical trials, NRXP will consider developing a follow-on product that is anticipated to achieve another 20 years of patent exclusivity.
NRXP recently announced data demonstrating that NRX-101 does not compromise the intestinal microbiome, unlike common antibiotics including Clindamycin and Ciprofloxacin. Should these findings be documented in human patients, NRX-101 would represent the only treatment for cUTI that does not cause C. Difficile infection.
Additionally, should NRXP or its partners succeed in serving 10% of the cUTI market, NRXP believes that the revenue from NRX-101 has the potential to be hundreds of million annually, based on 3 million cases per year in the US and potential pricing of over $3,500/course of therapy.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com/
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
On August 26th NRXP announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, NRXP has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. NRXP anticipates potential operations in the United States, France, and the United Kingdom.
More on TelAve News
- Nieves Ministries Leads with Faith to Fortify Safety, Education, and Puerto Rican Culture in Colorado
- Direct Interactions Honors Military Appreciation Month with Continued Specialty Hiring Practices
- Deadline Extended: More Time to Submit Your Proposal for the OpenSSL Conference 2025
- Pulitzer Prize Nominated Lauren Coyle Rosen Releases New Album, Covers and Veils in Blue
- Detroit Grand Prix High Profile Media Exposure, $100 Million Financing for Major Acquisition & Growth Strategy; Remote Lottery Platform: Lottery.com
This non-dilutive acquisition funding is in addition to the over $60 million in potential equity funding previously offered upon public listing of HOPE Therapeutics shares on a public exchange. Additional information to be presented by NRXP at upcoming HC Wainwright Annual Global Investment Conference in New York, September 9-11, 2024.
NRXP has formed partnerships to license clinical trial data from a French Government-funded trial and two NIH-funded trials all of which demonstrate efficacy of racemic Intravenous ketamine against depression and two of which demonstrate statistically significant benefit vs suicidality.
In March 2024 NRXP demonstrated the formulation of a pH neutral patentable form of IV ketamine that it anticipates will have widespread applicability both in treatment of depression and chronic pain.
NRXP presented final data from the recently completed phase 2b/3 trial of NRX-101 in suicidal bipolar depression4 at the American Society of Clinical Psychopharmacology's annual meeting. These data demonstrated a significantly improved safety profile versus the standard of care, as demonstrated by a clinically significant reduction in akathisia (P=0.025) and time to sustained remission from suicidality (P=0.05). Akathisia is an adverse event seen with antidepressant medications considered by many experts to be a precursor to suicide. Given the vital need for safer medications in this at-risk population, we plan to submit an NDA for Accelerated Approval to the US FDA for treatment of bipolar depression patients with suicidality or akathisia, based on these data as well as additional data from our STABIL-B5 trial.
HOPE Therapeutics, is an NXRP subsidiary that will focus on the delivery of advance psychiatric treatments, including ketamine-focused treatment for depression and suicidality. Unlike the core business of NRXP, that is focused on biotechnology Research and Development, HOPE is organized around consolidating existing best-in-class clinics into a nationwide network. This has been done previously and without much success with clinics that are not necessarily psychiatrist-led. With Hope ownership as an asset of NRXP, this will further strengthen the NRXP balance sheet and aims to further enhance shareholder value.
More on TelAve News
- Tomorrow's World Today Shines Bright with Four Telly Awards at the 46th Annual Telly Awards
- 6 Love Sports and Eight Sleep Announce Partnership Miami Women's Padel League Rebranded as the Eight Sleep Miami Women's Padel League by 6 Love Sports
- The TOBU RAILWAY X COFFEE PROJECT Supports Nikko Tourism and Fosters English Speaking Guides, Through November 27, 2026
- Al-Tabbaa & Hackett: Fixed Rates Improve For Savers
- Non-Citizen NY Travelers Face Extra Scrutiny at Local Airports: Attorney Robert Tsigler Featured in Gothamist
NRX-101 for Treatment of Chronic Pain:
In 2023, NRXP licensed US Patent 8,653,120 for the use of DCS in chronic pain and filed a now-accepted Investigational New Drug (IND) application with the FDA to initiate commercial drug development of NRX-101 in chronic pain. Data lock has now been achieved in a 200-person randomized prospective trial funded by the US DOD.
During Q3 2023, NRXP tested NRX-101 and its components against resistant pathogens that appear on the Congressionally mandated Qualified Infectious Disease Product (QIDP) list and proved in vitro effectiveness against antibiotic-resistant E. coli, Pseudomonas, and Acinetobacter. Accordingly, NRXP was granted QIDP designation, Fast Track Designation, and Priority Review by the US FDA in January 2024.
Should NRX-101 succeed in clinical trials, NRXP will consider developing a follow-on product that is anticipated to achieve another 20 years of patent exclusivity.
NRXP recently announced data demonstrating that NRX-101 does not compromise the intestinal microbiome, unlike common antibiotics including Clindamycin and Ciprofloxacin. Should these findings be documented in human patients, NRX-101 would represent the only treatment for cUTI that does not cause C. Difficile infection.
Additionally, should NRXP or its partners succeed in serving 10% of the cUTI market, NRXP believes that the revenue from NRX-101 has the potential to be hundreds of million annually, based on 3 million cases per year in the US and potential pricing of over $3,500/course of therapy.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com/
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
Filed Under: Business
0 Comments
Latest on TelAve News
- Lunch24You Inc. Presents AI-Driven School Meal Platform to Improve Youth Health and Food Literacy
- TimelyBill Wins Visionary Spotlight Award for Back Office and OSS Innovation
- TimelyBill Awarded Visionary Spotlight Award
- Prymax Media & Technology Group Acquires 'Hidden Treasures' From Estate of Jewel Records Founder Stan Lewis
- SMEs Face Major Disruption if Unprepared for 2027 Landline Switch-Off, Says Yellowcom
- Cooking with the Godfather Blends Family Tradition, Italian Flavor, and Leadership Wisdom
- Group Seeks End to Mandated Community Psychiatric Programs, Citing Global Alarm
- CoreIntegrator Announces Sage Intacct Approved A/P One Integration, Becoming an Official Sage Partner
- GENIUS EDGE DEFI™ Distributed Energy Flexible Infrastructure
- Enable Accessible Haircare Wins Bronze at 2025 NACD Packaging Awards
- Deshawn White and Oceans Chest Unveil Country Single "What I Can" from Upcoming Album Let God and Let Go
- RichMiner: Leading Cloud Mining Platform in 2025 - Advantage Analysis and Participation Guide
- Spiritually Transformative Events Based on Bhagavad Gita – Path to a Fulfilling Life
- Carnegie Hall Hosts Theatrical Concert: El Dorado – A Musical Portrait of Edgar Allan Poe
- Fashion Icon Karl Kani Enters NIL Era with First-Ever Athlete Signing: King Kendrick
- Mental Health Watchdog Calling for a Ban on the Use of the Electroshock Machine in Florida
- Global Patient Organizations Applaud Historic Passage of a Resolution at WHA 78: "Skin diseases as a global public health priority"
- The Great Reset, the First Photorealistic AI Film Makes History at the Cannes Film Festival
- Global Patient Organizations Applaud Historic Passage of Integrated Lung Health Resolution at World Health Assembly 78
- Love, Laughter, And Legacy Collide In The Romantic Comedy "different With Me"